bioRxiv Science⌕ Search

Biology subjects

Bokharaie, H.

Publications and source records attributed to Bokharaie, H..

2 recordsLinked to original sources

Expansion and collapse of VEGF diversity in major clades of the animal kingdom

The vascular endothelial growth factor (VEGF) family comprises in vertebrates five or six members: VEGF(-A), PlGF, VEGF-B, VEGF-C, VEGF-D, and - in venomous reptiles - VEGF-F. They fulfill mainly functions for the blood and lymphatic vascular systems. Together with the platelet-derived growth factors (PDGF-A to -D), they form the PDGF/VEGF subgroup among cystine-knot growth factors. Despite an absent vascular system in most invertebrates, PDGF/VEGF-like molecules have been found in, e.g., Drosophila melanogaster and Caenorhabditis elegans. The evolutionary relationship between PDGF and VEGF growth factors has only been addressed by older analyses, which were limited by the sparse sequencing data at the time. Here we perform a comprehensive analysis of the occurrence of PDGF/VEGF-like growth factors (PVFs) throughout all animal phyla and propose a likely phylogenetic tree. The three major vertebrate whole genome duplications play a role in the expansion of PDGF/VEGF diversity, but several limited duplications are necessary to account for the temporal pattern of emergence. The phylogenetically oldest PVFs likely featured a C-terminus with a BR3P signature, a hallmark of the modern-day lymphangiogenic growth factors VEGF-C and VEGF-D. Some of the younger VEGF genes appeared completely absent in some clades, e.g., functional VEGFB genes in the clade Archosauria, which includes crocodiles, birds, and other dinosaurs, and pgf in amphibians. The lack of precise counterparts for human genes poses limitations but also offers opportunities for research using organisms that diverge considerably from humans if the goal is to understand human physiology. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=181 HEIGHT=200 SRC="FIGDIR/small/507521v2_ufig1.gif" ALT="Figure 1"> View larger version (43K): org.highwire.dtl.DTLVardef@16b1abforg.highwire.dtl.DTLVardef@a91012org.highwire.dtl.DTLVardef@15e4994org.highwire.dtl.DTLVardef@1309753_HPS_FORMAT_FIGEXP M_FIG Sources for the graphical abstract: 326 MYA and older [1] 272-240 MYA [2] 235-65 MYA [3] C_FIG

evolutionary biology↗

Analysis of alternative mRNA splicing in vemuraf-enib-resistant melanoma cells

Alternative mRNA splicing is common in cancers. In BRAF V600E mutated malignant melanoma a frequent mechanism of acquired resistance to BRAF inhibitors involves alternative splicing (AS) of BRAF. The resulting shortened BRAF protein constitutively dimerizes and conveys drug resistance. Here, we have analysed AS in SKMEL-239 melanoma cells and a BRAF inhibitor (vemurafenib) resistant derivative that expresses an AS, shortened BRAF V600E transcript. Transcriptome analysis showed differential expression of spliceosome components between the two cell lines. As there is no consensus approach to analysing AS events, we used and compared four common AS softwares based on different principles, DEXSeq, rMATS, ASpli, and LeafCutter. Two of them correctly identified the BRAF V600E AS in the vemurafenib resistant cells. Only 12 AS events were identified by all four softwares. Testing the AS predictions experimentally showed that these overlapping predictions are highly accurate. Interestingly, they identified AS caused alterations in the expression of melanin synthesis and cell migration genes in the vemurafenib resistant cells. This analysis shows that combining different AS analysis approaches produce reliable results and meaningful, biologically testable hypotheses. Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=70 SRC="FIGDIR/small/484656v2_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@9f4920org.highwire.dtl.DTLVardef@179e9bcorg.highwire.dtl.DTLVardef@e05632org.highwire.dtl.DTLVardef@3b1c41_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗